Xcout Intel
Trogenix
Trogenix is a privately held biotechnology research company that stands at the forefront of cancer therapy innovation, combining genomics, synthetic biology, and oncology disease models. The company runs clinical trials, such as the Phase I/II trial for its TGX-007 gene therapy to treat glioblastoma.
Subscribe to see Trogenix’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Trogenix at a glance
Trogenix is a healthcare company headquartered in United Kingdom. Its most recent funding round, Series A, raised $95M in October 2025. Xcout tracks 6 named people at Trogenix, including Dr. Ken Macnamara (Chief Executive Officer).
Trogenix leadership
- Dr. Ken MacnamaraChief Executive Officer
- Dr. Juan Manuel IglesiasChief Technology Officer
- Atif Abbas, MDChief Medical Officer
- Dr. Dima KuzminChairman
- Prof. Steve PollardChief Scientific Officer and Founder
- Tay SalimullahChief Strategy Officer and Board Member
Trogenix funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $95M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Trogenix competitors
A few of Trogenix's closest competitors — see the full list of competitors and alternatives →
Imagenomix is a biotechnology research company headquartered in New York City that develops artificial intelligence models to enhance cancer clinical trials and precision medicine.
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
GEMMABio is a privately held therapeutics company founded in 2024 in Philadelphia, Pennsylvania, dedicated to developing novel gene therapies for rare diseases.
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Get Trogenix's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Trogenix in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access